SGIOY Shionogi & Co Unsp/Adrs
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. This is an ADR of a company whose stock trades outside of the U.S. as the symbol JT:4507.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$11.14 Pink
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: ADRs
Category3: Large cap
GICS sector: Health Care
Industry: Drug Manufacturers-Specialty &
Index country: Japan
Country of incorporation: Japan
IPO date: 11/30/2018
Outstanding shares: 1,229,544,660
Average volume: 185,356
Market cap: $13,697,127,512
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%